JP2007500705A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007500705A5 JP2007500705A5 JP2006522021A JP2006522021A JP2007500705A5 JP 2007500705 A5 JP2007500705 A5 JP 2007500705A5 JP 2006522021 A JP2006522021 A JP 2006522021A JP 2006522021 A JP2006522021 A JP 2006522021A JP 2007500705 A5 JP2007500705 A5 JP 2007500705A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- phenyl
- hydroxyphenyl
- tetramethylcyclohexylidene
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 30
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 7
- 201000009273 Endometriosis Diseases 0.000 claims 6
- 210000000988 bone and bone Anatomy 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 6
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 5
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- -1 4-hydroxy-2,3-dimethylphenyl Chemical group 0.000 claims 4
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 208000004746 Atrophic Vaginitis Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 208000014311 Cushing syndrome Diseases 0.000 claims 4
- 206010054089 Depressive symptom Diseases 0.000 claims 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims 4
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 4
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 206010063837 Reperfusion injury Diseases 0.000 claims 4
- 206010071018 Urogenital atrophy Diseases 0.000 claims 4
- 230000032683 aging Effects 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 230000035876 healing Effects 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 4
- 238000012423 maintenance Methods 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000011707 mineral Substances 0.000 claims 4
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 230000008733 trauma Effects 0.000 claims 4
- 230000001457 vasomotor Effects 0.000 claims 4
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 3
- 206010024421 Libido increased Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 210000003205 muscle Anatomy 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 230000008439 repair process Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 208000000819 Adrenocortical Hyperfunction Diseases 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 206010006298 Breast pain Diseases 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 206010058314 Dysplasia Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 208000036119 Frailty Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010019799 Hepatitis viral Diseases 0.000 claims 2
- 206010020112 Hirsutism Diseases 0.000 claims 2
- 206010020564 Hyperadrenocorticism Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000006662 Mastodynia Diseases 0.000 claims 2
- 208000029725 Metabolic bone disease Diseases 0.000 claims 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 206010029216 Nervousness Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 206010049088 Osteopenia Diseases 0.000 claims 2
- 208000027868 Paget disease Diseases 0.000 claims 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 2
- 206010036940 Prostatic adenoma Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039792 Seborrhoea Diseases 0.000 claims 2
- 208000030047 Sexual desire disease Diseases 0.000 claims 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims 2
- 206010049416 Short-bowel syndrome Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 206010067269 Uterine fibrosis Diseases 0.000 claims 2
- 206010047163 Vasospasm Diseases 0.000 claims 2
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 102000001307 androgen receptors Human genes 0.000 claims 2
- 108010080146 androgen receptors Proteins 0.000 claims 2
- 206010068168 androgenetic alopecia Diseases 0.000 claims 2
- 201000002996 androgenic alopecia Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 2
- 210000003433 aortic smooth muscle cell Anatomy 0.000 claims 2
- 206010003549 asthenia Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000006866 deterioration Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010013990 dysuria Diseases 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 210000004696 endometrium Anatomy 0.000 claims 2
- 102000015694 estrogen receptors Human genes 0.000 claims 2
- 108010038795 estrogen receptors Proteins 0.000 claims 2
- 206010016256 fatigue Diseases 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 2
- 201000008980 hyperinsulinism Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000002751 lymph Anatomy 0.000 claims 2
- 208000027202 mammary Paget disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000009245 menopause Effects 0.000 claims 2
- 230000003340 mental effect Effects 0.000 claims 2
- 230000027939 micturition Effects 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 210000004165 myocardium Anatomy 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 201000001245 periodontitis Diseases 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 201000011461 pre-eclampsia Diseases 0.000 claims 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 2
- 230000001107 psychogenic effect Effects 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000001076 sarcopenia Diseases 0.000 claims 2
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 2
- 230000037152 sensory function Effects 0.000 claims 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 208000018198 spasticity Diseases 0.000 claims 2
- 230000035882 stress Effects 0.000 claims 2
- 206010043554 thrombocytopenia Diseases 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 230000005740 tumor formation Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 208000019206 urinary tract infection Diseases 0.000 claims 2
- 210000004291 uterus Anatomy 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 201000001862 viral hepatitis Diseases 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- IIGBAYDKIWBPCU-AIHHMALZSA-N (2s)-1-[(e)-3-[4-[cycloheptylidene-(4-hydroxyphenyl)methyl]phenyl]prop-2-enoyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)\C=C\C1=CC=C(C(C=2C=CC(O)=CC=2)=C2CCCCCC2)C=C1 IIGBAYDKIWBPCU-AIHHMALZSA-N 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- NDEYJKKJWBKIIR-CAOOACKPSA-N (e)-3-[3-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]phenyl]prop-2-enoic acid Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C=1C=C(\C=C\C(O)=O)C=CC=1)C1=CC=C(O)C=C1 NDEYJKKJWBKIIR-CAOOACKPSA-N 0.000 claims 1
- PDQBWIBKUHIICJ-NTUHNPAUSA-N (e)-3-[3-chloro-4-[cyclohexylidene-(4-hydroxyphenyl)methyl]phenyl]prop-2-enoic acid Chemical compound ClC1=CC(/C=C/C(=O)O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCC1 PDQBWIBKUHIICJ-NTUHNPAUSA-N 0.000 claims 1
- MQANJDKHDUDLHH-KPKJPENVSA-N (e)-3-[4-[(3-chloro-4-hydroxyphenyl)-(2,2,6,6-tetramethyloxan-4-ylidene)methyl]phenyl]prop-2-enoic acid Chemical compound C1C(C)(C)OC(C)(C)CC1=C(C=1C=C(Cl)C(O)=CC=1)C1=CC=C(\C=C\C(O)=O)C=C1 MQANJDKHDUDLHH-KPKJPENVSA-N 0.000 claims 1
- IEEOYDJCAZMNFY-KPKJPENVSA-N (e)-3-[4-[(3-chloro-4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]prop-2-enoic acid Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=C(Cl)C(O)=CC=1)C1=CC=C(\C=C\C(O)=O)C=C1 IEEOYDJCAZMNFY-KPKJPENVSA-N 0.000 claims 1
- IFKHGIYQTGYJSS-NTEUORMPSA-N (e)-3-[4-[(3-chloro-4-hydroxyphenyl)-cycloheptylidenemethyl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C(C=1C=C(Cl)C(O)=CC=1)=C1CCCCCC1 IFKHGIYQTGYJSS-NTEUORMPSA-N 0.000 claims 1
- XLKZMOCPFOKRCN-MDWZMJQESA-N (e)-3-[4-[(3-chloro-4-hydroxyphenyl)-cyclohexylidenemethyl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C(C=1C=C(Cl)C(O)=CC=1)=C1CCCCC1 XLKZMOCPFOKRCN-MDWZMJQESA-N 0.000 claims 1
- MRIRQIZLHFUDJT-KPKJPENVSA-N (e)-3-[4-[(3-fluoro-4-hydroxyphenyl)-(2,2,6,6-tetramethyloxan-4-ylidene)methyl]phenyl]prop-2-enoic acid Chemical compound C1C(C)(C)OC(C)(C)CC1=C(C=1C=C(F)C(O)=CC=1)C1=CC=C(\C=C\C(O)=O)C=C1 MRIRQIZLHFUDJT-KPKJPENVSA-N 0.000 claims 1
- OMGMXYACDPFCEG-KPKJPENVSA-N (e)-3-[4-[(3-fluoro-4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]prop-2-enoic acid Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=C(F)C(O)=CC=1)C1=CC=C(\C=C\C(O)=O)C=C1 OMGMXYACDPFCEG-KPKJPENVSA-N 0.000 claims 1
- OLJWDJBIESYNEY-LFYBBSHMSA-N (e)-3-[4-[(4,4-dimethylcyclohexylidene)-(4-hydroxyphenyl)methyl]phenyl]prop-2-enoic acid Chemical compound C1CC(C)(C)CCC1=C(C=1C=CC(\C=C\C(O)=O)=CC=1)C1=CC=C(O)C=C1 OLJWDJBIESYNEY-LFYBBSHMSA-N 0.000 claims 1
- LNBGFCKFUBABPV-VGOFMYFVSA-N (e)-3-[4-[(4-hydroxyphenyl)-(2,2,6,6-tetramethyloxan-4-ylidene)methyl]phenyl]prop-2-enoic acid Chemical compound C1C(C)(C)OC(C)(C)CC1=C(C=1C=CC(\C=C\C(O)=O)=CC=1)C1=CC=C(O)C=C1 LNBGFCKFUBABPV-VGOFMYFVSA-N 0.000 claims 1
- NNFCEKYJMMYGOD-VGOFMYFVSA-N (e)-3-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]prop-2-enamide Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(\C=C\C(N)=O)=CC=1)C1=CC=C(O)C=C1 NNFCEKYJMMYGOD-VGOFMYFVSA-N 0.000 claims 1
- LBVZZPZACRTCIB-VGOFMYFVSA-N (e)-3-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]prop-2-enoic acid Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(\C=C\C(O)=O)=CC=1)C1=CC=C(O)C=C1 LBVZZPZACRTCIB-VGOFMYFVSA-N 0.000 claims 1
- OSQPSKQSEZRPPY-CCEZHUSRSA-N (e)-3-[4-[(4-hydroxyphenyl)-(oxan-4-ylidene)methyl]phenyl]-2-methylprop-2-enoic acid Chemical compound C1=CC(\C=C(/C)C(O)=O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCOCC1 OSQPSKQSEZRPPY-CCEZHUSRSA-N 0.000 claims 1
- NQIFKFNBTBROPX-XCVCLJGOSA-N (e)-3-[4-[(4-hydroxyphenyl)-(oxan-4-ylidene)methyl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCOCC1 NQIFKFNBTBROPX-XCVCLJGOSA-N 0.000 claims 1
- OLUZJHMLWRCIRT-XCVCLJGOSA-N (e)-3-[4-[(4-hydroxyphenyl)-(thian-4-ylidene)methyl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCSCC1 OLUZJHMLWRCIRT-XCVCLJGOSA-N 0.000 claims 1
- KNLYVVNUKJDQLW-NTEUORMPSA-N (e)-3-[4-[cycloheptylidene-(3-fluoro-4-hydroxyphenyl)methyl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C(C=1C=C(F)C(O)=CC=1)=C1CCCCCC1 KNLYVVNUKJDQLW-NTEUORMPSA-N 0.000 claims 1
- RACJIGDHWPWSOJ-OUKQBFOZSA-N (e)-3-[4-[cycloheptylidene-(3-hydroxyphenyl)methyl]-2-fluorophenyl]prop-2-enoic acid Chemical compound C1=C(F)C(/C=C/C(=O)O)=CC=C1C(C=1C=C(O)C=CC=1)=C1CCCCCC1 RACJIGDHWPWSOJ-OUKQBFOZSA-N 0.000 claims 1
- STGYOKWDZVFRNJ-NTCAYCPXSA-N (e)-3-[4-[cycloheptylidene-(3-hydroxyphenyl)methyl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C(C=1C=C(O)C=CC=1)=C1CCCCCC1 STGYOKWDZVFRNJ-NTCAYCPXSA-N 0.000 claims 1
- SGYCOKAIMUWWHK-SDNWHVSQSA-N (e)-3-[4-[cycloheptylidene-(4-hydroxyphenyl)methyl]-2-fluorophenyl]prop-2-enoic acid Chemical compound C1=C(F)C(/C=C/C(=O)O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCCC1 SGYCOKAIMUWWHK-SDNWHVSQSA-N 0.000 claims 1
- YEZMYWLJHQMEKH-CXUHLZMHSA-N (e)-3-[4-[cycloheptylidene-(4-hydroxyphenyl)methyl]phenyl]prop-2-enamide Chemical compound C1=CC(/C=C/C(=O)N)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCCC1 YEZMYWLJHQMEKH-CXUHLZMHSA-N 0.000 claims 1
- FIXMRJCBRFHJKY-CXUHLZMHSA-N (e)-3-[4-[cycloheptylidene-(4-hydroxyphenyl)methyl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCCC1 FIXMRJCBRFHJKY-CXUHLZMHSA-N 0.000 claims 1
- VUFJYXGYPUYTEQ-MDWZMJQESA-N (e)-3-[4-[cyclohexylidene-(2,3-difluoro-4-hydroxyphenyl)methyl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C(C=1C(=C(F)C(O)=CC=1)F)=C1CCCCC1 VUFJYXGYPUYTEQ-MDWZMJQESA-N 0.000 claims 1
- HLONBPXQNZKCTM-MDWZMJQESA-N (e)-3-[4-[cyclohexylidene-(2-fluoro-4-hydroxyphenyl)methyl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C(C=1C(=CC(O)=CC=1)F)=C1CCCCC1 HLONBPXQNZKCTM-MDWZMJQESA-N 0.000 claims 1
- MUSXRSKAGXTKQI-MDWZMJQESA-N (e)-3-[4-[cyclohexylidene-(3-fluoro-4-hydroxyphenyl)methyl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C(C=1C=C(F)C(O)=CC=1)=C1CCCCC1 MUSXRSKAGXTKQI-MDWZMJQESA-N 0.000 claims 1
- JMEZCGIITJETTP-NTEUORMPSA-N (e)-3-[4-[cyclohexylidene-(4-hydroxy-2-methylphenyl)methyl]phenyl]prop-2-enoic acid Chemical compound CC1=CC(O)=CC=C1C(C=1C=CC(\C=C\C(O)=O)=CC=1)=C1CCCCC1 JMEZCGIITJETTP-NTEUORMPSA-N 0.000 claims 1
- MFVFAHVLQFEBJH-NTEUORMPSA-N (e)-3-[4-[cyclohexylidene-(4-hydroxy-3-methylphenyl)methyl]phenyl]prop-2-enoic acid Chemical compound C1=C(O)C(C)=CC(C(=C2CCCCC2)C=2C=CC(\C=C\C(O)=O)=CC=2)=C1 MFVFAHVLQFEBJH-NTEUORMPSA-N 0.000 claims 1
- YVVYTWWQCLGBSD-JLHYYAGUSA-N (e)-3-[4-[cyclohexylidene-(4-hydroxyphenyl)methyl]-2-fluorophenyl]prop-2-enoic acid Chemical compound C1=C(F)C(/C=C/C(=O)O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCC1 YVVYTWWQCLGBSD-JLHYYAGUSA-N 0.000 claims 1
- ACHILXBCZRXRSO-SDNWHVSQSA-N (e)-3-[4-[cyclohexylidene-(4-hydroxyphenyl)methyl]-2-methylphenyl]prop-2-enoic acid Chemical compound C1=C(\C=C\C(O)=O)C(C)=CC(C(=C2CCCCC2)C=2C=CC(O)=CC=2)=C1 ACHILXBCZRXRSO-SDNWHVSQSA-N 0.000 claims 1
- VLPXUKHZHBUJFJ-NTUHNPAUSA-N (e)-3-[4-[cyclohexylidene-(4-hydroxyphenyl)methyl]-3-fluorophenyl]prop-2-enoic acid Chemical compound FC1=CC(/C=C/C(=O)O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCC1 VLPXUKHZHBUJFJ-NTUHNPAUSA-N 0.000 claims 1
- GBGHTHKZJPQDEL-OVCLIPMQSA-N (e)-3-[4-[cyclohexylidene-(4-hydroxyphenyl)methyl]phenyl]prop-2-enamide Chemical compound C1=CC(/C=C/C(=O)N)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCC1 GBGHTHKZJPQDEL-OVCLIPMQSA-N 0.000 claims 1
- GOPACCJWLSLIKG-OVCLIPMQSA-N (e)-3-[4-[cyclohexylidene-(4-hydroxyphenyl)methyl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCC1 GOPACCJWLSLIKG-OVCLIPMQSA-N 0.000 claims 1
- VMKODCXRLKSFFR-ISLYRVAYSA-N (e)-3-[4-[cyclooctylidene-(4-hydroxyphenyl)methyl]phenyl]-2-methylprop-2-enoic acid Chemical compound C1=CC(\C=C(/C)C(O)=O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCCCC1 VMKODCXRLKSFFR-ISLYRVAYSA-N 0.000 claims 1
- KCKMNQWYQVMVAR-LICLKQGHSA-N (e)-3-[4-[cyclooctylidene-(4-hydroxyphenyl)methyl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCCCC1 KCKMNQWYQVMVAR-LICLKQGHSA-N 0.000 claims 1
- MVKWPMBMEANCLC-VGOFMYFVSA-N (e)-3-[4-[cyclopentylidene-(4-hydroxyphenyl)methyl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCC1 MVKWPMBMEANCLC-VGOFMYFVSA-N 0.000 claims 1
- LHUATOCBPYWODS-WOJGMQOQSA-N 1-[(e)-3-[4-[cycloheptylidene-(4-hydroxyphenyl)methyl]phenyl]prop-2-enoyl]piperidine-3-carboxylic acid Chemical compound C1C(C(=O)O)CCCN1C(=O)\C=C\C1=CC=C(C(C=2C=CC(O)=CC=2)=C2CCCCCC2)C=C1 LHUATOCBPYWODS-WOJGMQOQSA-N 0.000 claims 1
- PAPPTBRXLMZUQW-CXUHLZMHSA-N 1-[(e)-3-[4-[cycloheptylidene-(4-hydroxyphenyl)methyl]phenyl]prop-2-enoyl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C(=O)\C=C\C1=CC=C(C(C=2C=CC(O)=CC=2)=C2CCCCCC2)C=C1 PAPPTBRXLMZUQW-CXUHLZMHSA-N 0.000 claims 1
- XYCIIMWSQYRCQR-UHFFFAOYSA-N 1-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1C(C=1C=CC(O)=CC=1)=C1CC(C)(C)CC(C)(C)C1 XYCIIMWSQYRCQR-UHFFFAOYSA-N 0.000 claims 1
- CCXLSRVVJKABDT-UHFFFAOYSA-N 2-[4-[(4-fluorophenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenoxy]acetic acid Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(OCC(O)=O)=CC=1)C1=CC=C(F)C=C1 CCXLSRVVJKABDT-UHFFFAOYSA-N 0.000 claims 1
- VAHOGTZVPKSBIK-UHFFFAOYSA-N 2-[4-[(4-fluorophenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenoxy]acetonitrile Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(OCC#N)=CC=1)C1=CC=C(F)C=C1 VAHOGTZVPKSBIK-UHFFFAOYSA-N 0.000 claims 1
- JCTACMKPKFHQPK-UHFFFAOYSA-N 2-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenoxy]acetic acid Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(OCC(O)=O)=CC=1)C1=CC=C(O)C=C1 JCTACMKPKFHQPK-UHFFFAOYSA-N 0.000 claims 1
- AUJKPDOYKWKHRS-UHFFFAOYSA-N 2-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenoxy]acetonitrile Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(OCC#N)=CC=1)C1=CC=C(O)C=C1 AUJKPDOYKWKHRS-UHFFFAOYSA-N 0.000 claims 1
- AVBTULZSRANEOV-UHFFFAOYSA-N 2-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]acetic acid Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(CC(O)=O)=CC=1)C1=CC=C(O)C=C1 AVBTULZSRANEOV-UHFFFAOYSA-N 0.000 claims 1
- HDKKZKFDXRMNFK-UHFFFAOYSA-N 2-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]benzoic acid Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C=1C(=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 HDKKZKFDXRMNFK-UHFFFAOYSA-N 0.000 claims 1
- GPLATJSRUMTQNL-UHFFFAOYSA-N 2-[4-[cycloheptylidene-(4-hydroxyphenyl)methyl]phenoxy]-2-methylpropanoic acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCCC1 GPLATJSRUMTQNL-UHFFFAOYSA-N 0.000 claims 1
- XSLDHJNGYVYIKF-UHFFFAOYSA-N 2-[4-[cycloheptylidene-(4-hydroxyphenyl)methyl]phenoxy]acetic acid Chemical compound C1=CC(OCC(=O)O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCCC1 XSLDHJNGYVYIKF-UHFFFAOYSA-N 0.000 claims 1
- YWJICDGEDGTZPW-UHFFFAOYSA-N 2-[4-[cycloheptylidene-(4-hydroxyphenyl)methyl]phenoxy]acetonitrile Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(OCC#N)=CC=1)=C1CCCCCC1 YWJICDGEDGTZPW-UHFFFAOYSA-N 0.000 claims 1
- BIWQNDCURCNWFY-UHFFFAOYSA-N 2-fluoro-4-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]benzonitrile Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C=1C=C(F)C(C#N)=CC=1)C1=CC=C(O)C=C1 BIWQNDCURCNWFY-UHFFFAOYSA-N 0.000 claims 1
- JGAPYXCUYNDKRK-UHFFFAOYSA-N 3-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]benzamide Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C=1C=C(C=CC=1)C(N)=O)C1=CC=C(O)C=C1 JGAPYXCUYNDKRK-UHFFFAOYSA-N 0.000 claims 1
- XHMUAVPRJQCENI-UHFFFAOYSA-N 3-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]benzoic acid Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C=1C=C(C=CC=1)C(O)=O)C1=CC=C(O)C=C1 XHMUAVPRJQCENI-UHFFFAOYSA-N 0.000 claims 1
- FDMCHUIWHLKNDZ-UHFFFAOYSA-N 3-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]propanoic acid Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(CCC(O)=O)=CC=1)C1=CC=C(O)C=C1 FDMCHUIWHLKNDZ-UHFFFAOYSA-N 0.000 claims 1
- AXSLABKKPZBWOT-UHFFFAOYSA-N 3-[4-[cycloheptylidene-(4-hydroxyphenyl)methyl]-3-fluorophenyl]prop-2-enoic acid Chemical compound FC1=CC(C=CC(=O)O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCCC1 AXSLABKKPZBWOT-UHFFFAOYSA-N 0.000 claims 1
- KWOWYVUSZAURIL-UHFFFAOYSA-N 4-[(4,4-dimethylcyclohexylidene)-(4-hydroxyphenyl)methyl]benzoic acid Chemical compound C1CC(C)(C)CCC1=C(C=1C=CC(=CC=1)C(O)=O)C1=CC=C(O)C=C1 KWOWYVUSZAURIL-UHFFFAOYSA-N 0.000 claims 1
- RUKFPTKRGLBUNZ-UHFFFAOYSA-N 4-[(4-ethynylphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C#C)C1=CC=C(O)C=C1 RUKFPTKRGLBUNZ-UHFFFAOYSA-N 0.000 claims 1
- VNWOTNLGPKGKNZ-UHFFFAOYSA-N 4-[(4-fluorophenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(F)=CC=1)C1=CC=C(O)C=C1 VNWOTNLGPKGKNZ-UHFFFAOYSA-N 0.000 claims 1
- GCSPKXTVZUWUGY-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]benzamide Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C(N)=O)C1=CC=C(O)C=C1 GCSPKXTVZUWUGY-UHFFFAOYSA-N 0.000 claims 1
- KNQLNDPHLXIOCY-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]benzoic acid Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C(O)=O)C1=CC=C(O)C=C1 KNQLNDPHLXIOCY-UHFFFAOYSA-N 0.000 claims 1
- WBWAVCSKYOMYND-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]benzonitrile Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C#N)C1=CC=C(O)C=C1 WBWAVCSKYOMYND-UHFFFAOYSA-N 0.000 claims 1
- LRSZZOSWVCKMBF-UHFFFAOYSA-N 4-[(4-methylsulfonylphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)S(C)(=O)=O)C1=CC=C(O)C=C1 LRSZZOSWVCKMBF-UHFFFAOYSA-N 0.000 claims 1
- GQCTZOUBYRQJKD-UHFFFAOYSA-N 4-[(4-pyridin-3-ylphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C=1C=NC=CC=1)C1=CC=C(O)C=C1 GQCTZOUBYRQJKD-UHFFFAOYSA-N 0.000 claims 1
- ARGWGYWORPPIHS-UHFFFAOYSA-N 4-[(4-pyrimidin-5-ylphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C=1C=NC=NC=1)C1=CC=C(O)C=C1 ARGWGYWORPPIHS-UHFFFAOYSA-N 0.000 claims 1
- BHBZKTMKZSJMSZ-UHFFFAOYSA-N 4-[4-[(4-fluorophenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenoxy]butanoic acid Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(OCCCC(O)=O)=CC=1)C1=CC=C(F)C=C1 BHBZKTMKZSJMSZ-UHFFFAOYSA-N 0.000 claims 1
- FJXWRAFMJUWSEX-UHFFFAOYSA-N 4-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenoxy]butanoic acid Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(OCCCC(O)=O)=CC=1)C1=CC=C(O)C=C1 FJXWRAFMJUWSEX-UHFFFAOYSA-N 0.000 claims 1
- DMSRKOKMKKANQI-UHFFFAOYSA-N 4-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]benzoic acid Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C=1C=CC(=CC=1)C(O)=O)C1=CC=C(O)C=C1 DMSRKOKMKKANQI-UHFFFAOYSA-N 0.000 claims 1
- LOMGCJFGNCGBFK-UHFFFAOYSA-N 4-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]benzonitrile Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C=1C=CC(=CC=1)C#N)C1=CC=C(O)C=C1 LOMGCJFGNCGBFK-UHFFFAOYSA-N 0.000 claims 1
- WRVKEFGJCPYAFI-UHFFFAOYSA-N 4-[4-[cycloheptylidene-(4-hydroxyphenyl)methyl]phenoxy]butanoic acid Chemical compound C1=CC(OCCCC(=O)O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCCC1 WRVKEFGJCPYAFI-UHFFFAOYSA-N 0.000 claims 1
- RAGPADQHQMVAIT-UHFFFAOYSA-N 4-[4-[cyclooctylidene-(4-hydroxyphenyl)methyl]phenyl]benzonitrile Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(=CC=1)C=1C=CC(=CC=1)C#N)=C1CCCCCCC1 RAGPADQHQMVAIT-UHFFFAOYSA-N 0.000 claims 1
- ZUDHDFBBUYVYOW-UHFFFAOYSA-N 4-[[4-(1,3-oxazol-2-yl)phenyl]-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C=1OC=CN=1)C1=CC=C(O)C=C1 ZUDHDFBBUYVYOW-UHFFFAOYSA-N 0.000 claims 1
- LNZKRHSJBMRZJH-UHFFFAOYSA-N 4-[[4-(1h-pyrrol-2-yl)phenyl]-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C=1NC=CC=1)C1=CC=C(O)C=C1 LNZKRHSJBMRZJH-UHFFFAOYSA-N 0.000 claims 1
- PKKRRWSNZMRZIB-UHFFFAOYSA-N 4-[[4-(2-hydroxyethoxy)phenyl]-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(OCCO)=CC=1)C1=CC=C(O)C=C1 PKKRRWSNZMRZIB-UHFFFAOYSA-N 0.000 claims 1
- WHDZZERRMRSOJT-UHFFFAOYSA-N 4-[[4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound CC1=NOC(C)=C1C1=CC=C(C(=C2CC(C)(C)CC(C)(C)C2)C=2C=CC(O)=CC=2)C=C1 WHDZZERRMRSOJT-UHFFFAOYSA-N 0.000 claims 1
- RDYKHLKPTKSFDO-UHFFFAOYSA-N 4-[[4-(3-hydroxy-3-methylbut-1-ynyl)phenyl]-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1=CC(C#CC(C)(O)C)=CC=C1C(C=1C=CC(O)=CC=1)=C1CC(C)(C)CC(C)(C)C1 RDYKHLKPTKSFDO-UHFFFAOYSA-N 0.000 claims 1
- JMQSFGWSEWUDFH-UHFFFAOYSA-N 4-[[4-(3-hydroxyprop-1-ynyl)phenyl]-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C#CCO)C1=CC=C(O)C=C1 JMQSFGWSEWUDFH-UHFFFAOYSA-N 0.000 claims 1
- QLJAGPVADKRYPP-UHFFFAOYSA-N 4-[[4-(3-hydroxypropyl)phenyl]-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(CCCO)=CC=1)C1=CC=C(O)C=C1 QLJAGPVADKRYPP-UHFFFAOYSA-N 0.000 claims 1
- OSGUMTWQWSBKJP-UHFFFAOYSA-N 4-[[4-(4-hydroxybut-1-ynyl)phenyl]-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C#CCCO)C1=CC=C(O)C=C1 OSGUMTWQWSBKJP-UHFFFAOYSA-N 0.000 claims 1
- BZUAYEMWQUKTGB-UHFFFAOYSA-N 4-[[4-(4-methylsulfonylphenyl)phenyl]-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C=1C=CC(=CC=1)S(C)(=O)=O)C1=CC=C(O)C=C1 BZUAYEMWQUKTGB-UHFFFAOYSA-N 0.000 claims 1
- PANUZDDPOYASPL-UHFFFAOYSA-N 4-[[4-(4-morpholin-4-ylphenyl)phenyl]-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C=1C=CC(=CC=1)N1CCOCC1)C1=CC=C(O)C=C1 PANUZDDPOYASPL-UHFFFAOYSA-N 0.000 claims 1
- QBXFLDPRURHCQO-UHFFFAOYSA-N 4-[[4-(furan-3-yl)phenyl]-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C1=COC=C1)C1=CC=C(O)C=C1 QBXFLDPRURHCQO-UHFFFAOYSA-N 0.000 claims 1
- FGOSOYNMBQWRDW-UHFFFAOYSA-N 4-[[4-[2-(2-hydroxyethoxy)ethoxy]phenyl]-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(OCCOCCO)=CC=1)C1=CC=C(O)C=C1 FGOSOYNMBQWRDW-UHFFFAOYSA-N 0.000 claims 1
- HQLHBMBRYHUEKB-UHFFFAOYSA-N 4-[[4-[2-(hydroxymethyl)phenyl]phenyl]-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C=1C(=CC=CC=1)CO)C1=CC=C(O)C=C1 HQLHBMBRYHUEKB-UHFFFAOYSA-N 0.000 claims 1
- WPYIUUAOIZBGEM-UHFFFAOYSA-N 4-[[4-[3-(hydroxymethyl)phenyl]phenyl]-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C=1C=C(CO)C=CC=1)C1=CC=C(O)C=C1 WPYIUUAOIZBGEM-UHFFFAOYSA-N 0.000 claims 1
- HSXMWIZGUPNDET-UHFFFAOYSA-N 4-[[4-[4-(hydroxymethyl)phenyl]phenyl]-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C=1C=CC(CO)=CC=1)C1=CC=C(O)C=C1 HSXMWIZGUPNDET-UHFFFAOYSA-N 0.000 claims 1
- ZCFPIWGUWPNBFW-UHFFFAOYSA-N 4-[cycloheptylidene-(3-fluoro-4-hydroxyphenyl)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(C=1C=C(F)C(O)=CC=1)=C1CCCCCC1 ZCFPIWGUWPNBFW-UHFFFAOYSA-N 0.000 claims 1
- ZRTBSOOBAPFVNL-UHFFFAOYSA-N 4-[cycloheptylidene-(4-hydroxyphenyl)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCCC1 ZRTBSOOBAPFVNL-UHFFFAOYSA-N 0.000 claims 1
- RAIGTEDNQZTYRX-UHFFFAOYSA-N 4-[cycloheptylidene-(4-hydroxyphenyl)methyl]benzonitrile Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(=CC=1)C#N)=C1CCCCCC1 RAIGTEDNQZTYRX-UHFFFAOYSA-N 0.000 claims 1
- PFBYGLQXMPMCKW-UHFFFAOYSA-N 4-[cycloheptylidene-[4-(1-hydroxy-2-methylpropan-2-yl)oxyphenyl]methyl]phenol Chemical compound C1=CC(OC(C)(CO)C)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCCC1 PFBYGLQXMPMCKW-UHFFFAOYSA-N 0.000 claims 1
- MGPXFXGKBAMYMV-UHFFFAOYSA-N 4-[cycloheptylidene-[4-(2-hydroxyethoxy)phenyl]methyl]phenol Chemical compound C1=CC(OCCO)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCCC1 MGPXFXGKBAMYMV-UHFFFAOYSA-N 0.000 claims 1
- OQAVAAMXESTSFG-UHFFFAOYSA-N 4-[cycloheptylidene-[4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]methyl]phenol Chemical compound CC1=NOC(C)=C1C1=CC=C(C(C=2C=CC(O)=CC=2)=C2CCCCCC2)C=C1 OQAVAAMXESTSFG-UHFFFAOYSA-N 0.000 claims 1
- HPCNVMKSUBSABB-UHFFFAOYSA-N 4-[cycloheptylidene-[4-(5-hydroxypent-1-ynyl)phenyl]methyl]phenol Chemical compound C1=CC(C#CCCCO)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCCC1 HPCNVMKSUBSABB-UHFFFAOYSA-N 0.000 claims 1
- YDNGTCILGJQIIQ-UHFFFAOYSA-N 4-[cycloheptylidene-[4-(furan-2-yl)phenyl]methyl]phenol Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(=CC=1)C=1OC=CC=1)=C1CCCCCC1 YDNGTCILGJQIIQ-UHFFFAOYSA-N 0.000 claims 1
- VUUJOQMLARECBF-UHFFFAOYSA-N 4-[cycloheptylidene-[4-(furan-3-yl)phenyl]methyl]phenol Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(=CC=1)C1=COC=C1)=C1CCCCCC1 VUUJOQMLARECBF-UHFFFAOYSA-N 0.000 claims 1
- MVZHSFMGDOQTGN-UHFFFAOYSA-N 4-[cyclohexylidene-(4-hydroxyphenyl)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCC1 MVZHSFMGDOQTGN-UHFFFAOYSA-N 0.000 claims 1
- DSQRTGHJYKPKAY-UHFFFAOYSA-N 4-[cyclooctylidene-(4-hydroxyphenyl)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCCCC1 DSQRTGHJYKPKAY-UHFFFAOYSA-N 0.000 claims 1
- DNFGDXIXXZROGO-UHFFFAOYSA-N 4-[cyclooctylidene-[4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]methyl]phenol Chemical compound CC1=NOC(C)=C1C1=CC=C(C(C=2C=CC(O)=CC=2)=C2CCCCCCC2)C=C1 DNFGDXIXXZROGO-UHFFFAOYSA-N 0.000 claims 1
- GFTUPAFVSDJXLA-UHFFFAOYSA-N 4-[cyclooctylidene-[4-(furan-2-yl)phenyl]methyl]phenol Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(=CC=1)C=1OC=CC=1)=C1CCCCCCC1 GFTUPAFVSDJXLA-UHFFFAOYSA-N 0.000 claims 1
- SZMCTPRSHURXFU-UHFFFAOYSA-N 4-[cyclooctylidene-[4-(furan-3-yl)phenyl]methyl]phenol Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(=CC=1)C1=COC=C1)=C1CCCCCCC1 SZMCTPRSHURXFU-UHFFFAOYSA-N 0.000 claims 1
- YMMAHSOALIHUIC-UHFFFAOYSA-N 5-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]pent-4-ynoic acid Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C#CCCC(O)=O)C1=CC=C(O)C=C1 YMMAHSOALIHUIC-UHFFFAOYSA-N 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- 208000004483 Dyspareunia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- JQMXBRNTYWEFOD-ISLYRVAYSA-N [(e)-2-[4-[cycloheptylidene-(4-hydroxyphenyl)methyl]phenyl]ethenyl]-ethoxyphosphinic acid Chemical compound C1=CC(/C=C/P(O)(=O)OCC)=CC=C1C(C=1C=CC(O)=CC=1)=C1CCCCCC1 JQMXBRNTYWEFOD-ISLYRVAYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 230000003416 augmentation Effects 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- FNIATMYXUPOJRW-UHFFFAOYSA-N cyclohexylidene Chemical group [C]1CCCCC1 FNIATMYXUPOJRW-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- GIXNKLDQTOGANE-UHFFFAOYSA-N n-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C(C=1C=CC(O)=CC=1)=C1CC(C)(C)CC(C)(C)C1 GIXNKLDQTOGANE-UHFFFAOYSA-N 0.000 claims 1
- XQJWAVQFRPTEQX-UHFFFAOYSA-N n-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]benzenesulfonamide Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(NS(=O)(=O)C=2C=CC=CC=2)=CC=1)C1=CC=C(O)C=C1 XQJWAVQFRPTEQX-UHFFFAOYSA-N 0.000 claims 1
- XJMMMTBWPRICTE-UHFFFAOYSA-N n-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]methanesulfonamide Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(NS(C)(=O)=O)=CC=1)C1=CC=C(O)C=C1 XJMMMTBWPRICTE-UHFFFAOYSA-N 0.000 claims 1
- PFLBJGZHJKDSIT-UHFFFAOYSA-N n-[4-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CC=C(C(=C2CC(C)(C)CC(C)(C)C2)C=2C=CC(O)=CC=2)C=C1 PFLBJGZHJKDSIT-UHFFFAOYSA-N 0.000 claims 1
- DDYXJHBDEXURAL-UHFFFAOYSA-N n-[4-[4-[(4-hydroxyphenyl)-(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl]phenyl]methanesulfonamide Chemical compound C1C(C)(C)CC(C)(C)CC1=C(C=1C=CC(=CC=1)C=1C=CC(NS(C)(=O)=O)=CC=1)C1=CC=C(O)C=C1 DDYXJHBDEXURAL-UHFFFAOYSA-N 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49058803P | 2003-07-28 | 2003-07-28 | |
| US60/490,588 | 2003-07-28 | ||
| PCT/US2004/024308 WO2005012220A2 (en) | 2003-07-28 | 2004-07-27 | Cycloalkylidene compounds as modulators of estrogen receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007500705A JP2007500705A (ja) | 2007-01-18 |
| JP2007500705A5 true JP2007500705A5 (https=) | 2007-05-10 |
| JP5013593B2 JP5013593B2 (ja) | 2012-08-29 |
Family
ID=34115412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522021A Expired - Fee Related JP5013593B2 (ja) | 2003-07-28 | 2004-07-27 | 化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7560589B2 (https=) |
| EP (1) | EP1667955A2 (https=) |
| JP (1) | JP5013593B2 (https=) |
| KR (1) | KR20060066070A (https=) |
| CN (1) | CN1856461A (https=) |
| AU (1) | AU2004261627C1 (https=) |
| BR (1) | BRPI0413013A (https=) |
| CA (1) | CA2533812C (https=) |
| IL (1) | IL173192A0 (https=) |
| MA (1) | MA28015A1 (https=) |
| MX (1) | MXPA06001094A (https=) |
| NO (1) | NO20060403L (https=) |
| NZ (1) | NZ545032A (https=) |
| RU (1) | RU2345981C2 (https=) |
| WO (1) | WO2005012220A2 (https=) |
| ZA (1) | ZA200600819B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723393B2 (en) | 2005-05-25 | 2010-05-25 | Glaxosmithkline Llc | Cycloalkylidene compounds as selective estrogen receptor modulators |
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| CN101370380A (zh) * | 2005-11-22 | 2009-02-18 | 史密丝克莱恩比彻姆公司 | 化合物 |
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| NZ572073A (en) | 2006-04-20 | 2011-09-30 | Janssen Pharmaceutica Nv | Heterocyclic compounds as inhibitors of c-fms kinase |
| BRPI0710548B8 (pt) | 2006-04-20 | 2021-05-25 | Janssen Pharmaceutica Nv | inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica |
| WO2008030771A1 (en) * | 2006-09-08 | 2008-03-13 | Smithkline Beecham Corporation | Cyclic alkylidene compounds as selective estrogen receptor modulators |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| CN102786394B (zh) * | 2012-07-30 | 2017-03-01 | 中国医学科学院医药生物技术研究所 | 取代双芳基亚甲基环烷基衍生物及其制备方法和应用 |
| JP6290884B2 (ja) | 2012-08-07 | 2018-03-07 | ヤンセン ファーマシューティカ エヌ．ベー． | ｃ−ＦＭＳキナーゼ阻害剤の調製プロセス |
| IN2015DN00659A (https=) | 2012-08-07 | 2015-06-26 | Janssen Pharmaceutica Nv | |
| RU2525397C2 (ru) * | 2012-09-10 | 2014-08-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" | 1-(4-этилфенил)-2-[3-(4-этилфенил)-2-(1н)-хиноксалинилиден]-1-этанон, обладающий анальгетической активностью |
| TWI653235B (zh) * | 2013-05-28 | 2019-03-11 | 阿斯特捷利康公司 | 作為抗癌劑之吲哚衍生物 |
| WO2015026990A2 (en) | 2013-08-20 | 2015-02-26 | University Of Washington Through Its Center For Commercialization | Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydrolase |
| CN107849072B (zh) | 2015-06-12 | 2020-12-15 | 西蒙弗雷泽大学 | 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途 |
| AU2021255723A1 (en) * | 2020-04-17 | 2022-12-08 | Essa Pharma, Inc. | Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof |
| US20240383930A1 (en) * | 2021-10-01 | 2024-11-21 | University Of Fukui | Method for producing vinylphosphonic acid monoester |
| WO2024245169A1 (zh) * | 2023-05-26 | 2024-12-05 | 北京盛诺基医药科技股份有限公司 | 一种靶向雌激素受体的protac化合物及其制备方法和用途 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB971908A (en) * | 1960-11-22 | 1964-10-07 | Ferrosan Ab | Dihydroxybenzhydrylidene cycloalkanes and derivatives thereof |
| US3760007A (en) | 1970-06-11 | 1973-09-18 | Schering Corp | Bicyclic benzhydrylidene derivatives |
| US3936493A (en) | 1973-04-17 | 1976-02-03 | Ortho Pharmaceutical Corporation | Diarylmethylenes |
| EP0273647B1 (en) | 1986-12-27 | 1992-03-11 | Takeda Chemical Industries, Ltd. | Coumaran derivatives, their production and use |
| SU1680693A1 (ru) * | 1987-03-25 | 1991-09-30 | Институт Органического Синтеза Ан Латвсср | Этил-3-(2,2-диметил-2-этилгидразиний)пропионат иодистый, про вл ющий антиаритмическую активность |
| DE3731913A1 (de) | 1987-09-23 | 1989-04-06 | Hoechst Ag | Pharmazeutische praeparate enthaltend ein 7-diphenylmethylenbicycloheptan- oder 7-diphenylmethylenbicyclohepten-derivat, die verwendung dieser verbindungen als arzneimittel sowie neue 7-diphenylmethylenbicycloheptane und 7-diphenylmethylenbicloheptene und verfahren zu ihrer herstellung |
| JP2876060B2 (ja) | 1989-04-03 | 1999-03-31 | 株式会社リコー | 電子写真感光体 |
| US5132190A (en) | 1989-04-10 | 1992-07-21 | Mitsui Toatsu Chemicals Incorporated | Hydrozones and electrophotographic photoreceptors comprising them |
| JPH02285356A (ja) | 1989-04-26 | 1990-11-22 | Kao Corp | 電子写真感光体 |
| JPH0315853A (ja) | 1989-06-14 | 1991-01-24 | Kao Corp | 電子写真感光体 |
| JPH03158852A (ja) | 1989-11-17 | 1991-07-08 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料の処理方法及び定着能を有した組成物 |
| CA2093798C (en) | 1990-10-10 | 2000-02-01 | John J. Piwinski | Pyridine and pyridine n-oxide derivatives of diaryl methyl piperidines or piperazines, and compositions and methods of use thereof |
| CA2109426A1 (en) | 1991-04-30 | 1992-10-31 | Hiroyuki Kouji | Triphenylethylene derivative and pharmaceutical drug containing the same |
| JPH0651546A (ja) | 1991-07-19 | 1994-02-25 | Ricoh Co Ltd | 電子写真用感光体 |
| US5962731A (en) | 1992-04-22 | 1999-10-05 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
| WO1993024446A1 (en) * | 1992-06-02 | 1993-12-09 | The Australian National University | Anthelmintic and/or nematocidal compounds |
| US5306752A (en) | 1992-10-09 | 1994-04-26 | Loctite Corporation | Cyanoacrylate adhesives utilizing quinoid compound polymer stabilizer |
| WO1994015901A1 (en) | 1993-01-11 | 1994-07-21 | Ligand Pharmaceuticals Inc. | Compounds having selectivity for retinoid x receptors |
| JPH06332206A (ja) | 1993-05-26 | 1994-12-02 | Konica Corp | 電子写真感光体及び電子写真法 |
| DE19526146A1 (de) | 1995-07-07 | 1997-01-09 | Schering Ag | Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
| LV11727B (en) * | 1995-08-21 | 1997-08-20 | Kalvins Ivars | Pharmaceutical composition |
| AU715528B2 (en) | 1995-09-08 | 2000-02-03 | Karo Bio Ab | Orphan receptor |
| FR2751964B1 (fr) | 1996-08-01 | 1998-10-30 | Union Pharma Scient Appl | Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique |
| TW548271B (en) | 1996-12-20 | 2003-08-21 | Astra Pharma Inc | Novel piperidine derivatives having an exocyclic double bond with analgesic effects |
| EP1000925A4 (en) | 1997-06-17 | 2001-08-08 | Sumitomo Chemical Co | TRIPHENYLMETHANE DERIVATIVES AND THEIR USE |
| BR9811946A (pt) * | 1997-08-15 | 2000-08-22 | Univ Duke | Método para prevenção ou tratamento de distúrbios e doenças dependentes de estrogênio |
| TW593256B (en) | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| US6787764B2 (en) * | 2000-02-18 | 2004-09-07 | Bruker Daltonics, Inc. | Method and apparatus for automating a matrix-assisted laser desorption/ionization (MALDI) mass spectrometer |
| EP1263758A2 (en) | 2000-03-03 | 2002-12-11 | Ortho-McNeil Pharmaceutical, Inc. | 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
| JP2002008865A (ja) | 2000-06-23 | 2002-01-11 | Matsushita Electric Ind Co Ltd | 有機電界発光素子 |
| ATE283853T1 (de) | 2000-09-20 | 2004-12-15 | Schering Corp | Substituierte imidazole als duale histamine h1 und h3 agonisten oder antagonisten |
| WO2003016270A2 (en) | 2001-08-11 | 2003-02-27 | Bristol-Myers Squibb Pharma Company | Selective estrogen receptor modulators |
| US7723393B2 (en) * | 2005-05-25 | 2010-05-25 | Glaxosmithkline Llc | Cycloalkylidene compounds as selective estrogen receptor modulators |
-
2004
- 2004-07-27 BR BRPI0413013-8A patent/BRPI0413013A/pt not_active IP Right Cessation
- 2004-07-27 MX MXPA06001094A patent/MXPA06001094A/es active IP Right Grant
- 2004-07-27 EP EP04779374A patent/EP1667955A2/en not_active Withdrawn
- 2004-07-27 US US10/565,296 patent/US7560589B2/en not_active Expired - Fee Related
- 2004-07-27 RU RU2006101632/04A patent/RU2345981C2/ru not_active IP Right Cessation
- 2004-07-27 KR KR1020067001919A patent/KR20060066070A/ko not_active Ceased
- 2004-07-27 NZ NZ545032A patent/NZ545032A/en unknown
- 2004-07-27 JP JP2006522021A patent/JP5013593B2/ja not_active Expired - Fee Related
- 2004-07-27 CA CA2533812A patent/CA2533812C/en not_active Expired - Fee Related
- 2004-07-27 CN CNA2004800279546A patent/CN1856461A/zh active Pending
- 2004-07-27 AU AU2004261627A patent/AU2004261627C1/en not_active Ceased
- 2004-07-27 WO PCT/US2004/024308 patent/WO2005012220A2/en not_active Ceased
-
2006
- 2006-01-17 IL IL173192A patent/IL173192A0/en unknown
- 2006-01-25 NO NO20060403A patent/NO20060403L/no not_active Application Discontinuation
- 2006-01-27 ZA ZA200600819A patent/ZA200600819B/en unknown
- 2006-02-27 MA MA28844A patent/MA28015A1/fr unknown
-
2007
- 2007-05-14 US US11/748,096 patent/US7569601B2/en not_active Expired - Fee Related
-
2009
- 2009-06-08 US US12/480,097 patent/US7799828B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007500705A5 (https=) | ||
| CA2533812A1 (en) | Substituted cycloalkylidene compounds | |
| JP5313229B2 (ja) | スフィンゴシン１−リン酸（ｓ１ｐ）アゴニストとして用いるためのオキサジアゾール置換インダゾール誘導体 | |
| RU2437877C2 (ru) | Новые производные тиофена в качестве агонистов рецептора s1p1/edg1 | |
| US7875745B2 (en) | Compounds having lysophosphatidic acid receptor antagonism and uses thereof | |
| ES2243276T3 (es) | Derivados de tiazol y de oxazol y su uso farmaceutico. | |
| US7582803B2 (en) | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | |
| JP5244863B2 (ja) | ジオキサン−２−アルキルカルバメート誘導体の製造法およびその中間体 | |
| JP5481395B2 (ja) | 新規なアミノメチルベンゼン誘導体 | |
| JP5476467B2 (ja) | 新規なビフェニルピリジンアミドおよびフェニルピリジンアミド | |
| BRPI0716171B1 (pt) | Composto, composição farmacêutica e uso de um composto | |
| JP2004504320A (ja) | β３アドレナリン作動性アゴニスト | |
| JP2008503588A5 (https=) | ||
| JPWO2006059744A1 (ja) | ペルオキシソーム増殖剤活性化受容体δの活性化剤 | |
| WO2009012650A1 (en) | Aryl pyrimidine derivatives, preparation methods and pharmaceutical uses thereof | |
| RU2006145200A (ru) | Химические соединения | |
| JP2007523952A5 (https=) | ||
| JP2008545699A5 (https=) | ||
| KR900005011B1 (ko) | 5-아실-2-(1h)-피리디논 및 그의 제조방법 | |
| MXPA06005915A (es) | N-alquil pirroles como inhibidores de la hmg-coa reductasa. | |
| CN101304984A (zh) | 唑和噻唑ppar调节剂 | |
| MXPA06006396A (es) | Inhibidores de hmg-coa reductasa basados en imidazol. | |
| RU2144533C1 (ru) | Производные тетразола, способ их получения и фармацевтические композиции на их основе | |
| CN1265643A (zh) | 邻氨基苯甲酸类似物 | |
| JP7616609B2 (ja) | Ｒｎａウイルス感染症を処置する為のアリール－ｎ－アリール誘導体 |